For a Brighter Tomorrow

Innovative technology transforming injectable treatments into oral therapies

Oramed Pharmaceutical’s (Nasdaq: ORMP) flagship product, an oral insulin capsule, has the potential to better the lives of millions of people around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier – without fear of needles.

Pipeline

Investors

Edit Content

01 Pipeline

ORMD-0801 (Oral Insulin) Diabetes

ORMD-0801 (Oral Insulin) NASH

ORMD-0901 (Oral GLP-1)

Edit Content

02 Technology

The attractive advantages of oral drug delivery, including increased patient comfort and compliance, reduced risk of infection, simpler application in pediatric medicine, first-pass metabolism preceding systemic exposure, and cost effectiveness, have positioned it the most popular and preferred route of drug administration.